Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review (Q37992672)

26 August 2017

Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review (English)

1 reference

26 August 2017

1 reference

Fumitaka Koga

1

1 reference

PubMed ID

22409269

26 August 2017

Kazunori Kihara

series ordinal

2

1 reference

PubMed ID

22409269

26 August 2017

language of work or name

1 reference

12 March 2012

1 reference

International Journal of Urology

26 August 2017

1 reference

26 August 2017

19

1 reference

26 August 2017

5

1 reference

26 August 2017

388-401

1 reference

Complications after radical cystectomy: analysis of population-based data

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Bladder preservation: optimizing radiotherapy and integrated treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Trimodality treatment and selective organ preservation for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Early complications of cystectomy after high dose pelvic radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemoth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Combined modality treatment with bladder preservation for muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Risk factors for mortality and morbidity related to radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Neobladder formation after pelvic irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Impact of body mass index on radical cystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Contemporary open radical cystectomy: analysis of perioperative outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Preoperative concurrent chemoradiotherapy against muscle-invasive bladder cancer: results of partial cystectomy in elderly or high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Gasless single-port access endoscopic surgery in urology: minimum incision endoscopic surgery, MIES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Targeting the dynamic HSP90 complex in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Distressful symptoms after radical radiotherapy for urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02974.X

10.1111/J.1442-2042.2012.02974.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22409269